RESUMO
In order to evaluate the usefulness of the mitotic index (MI) and the Ki-67 nuclear antigen labeling index (Ki67LI) in pre-treatment biopsy specimens as predictors of response to chemotherapy for uterine cervical carcinomas, twelve patients with squamous cell carcinoma who received neoadjuvant chemotherapy before radical surgery were investigated. The MI and computer-quantitated Ki67LI were determined using H&E and immunostained slides of biopsy specimens collected before chemotherapy. Tumor size was measured three-dimensionally by MR imaging, and assessed before and after chemotherapy. We compared the values of MI and Ki67LI with changes in tumor size and the following results were obtained. 1) The percentage reduction in tumor size ranged from 0 to 98%. The MI ranged from 0.5 to 15, and Ki67LI ranged from 0.01 to 50.1%. 2) A significant positive correlation was observed between response to chemotherapy assessed on MR image and MI [Spearman's correlation coefficient (r) =0.66, n=12, p=0.027], and between response to chemotherapy and Ki67LI (r=0.72, n=12, p=0.017). 3) A significant correlation was observed between MI and computer-assessed Ki67 LI [Pearson's correlation coefficient (r) =0.80, n=12, p=0.002]. Therefore, pre-chemotherapy MI and Ki67LI were both good predictors of response to platinum-based chemotherapy. Because MI is technically more convenient and economically less expensive than computer-quantitated Ki67LI, MI remains a simple and reliable predictor from the clinical point of view.